IL1B and diabetes mellitus: An anti-inflammatory effect of silymarin has been described in the liver tissue, in diabetes, or in experimental inflammatory bowel disease; there is evidence that silymarin regulates several inflammatory mediators such as tumoral necrosis factor-alpha (TNF-α), interleukin (IL-1β, IL-6, and IL-1) receptor antagonists, and nitric oxide.